[253 Pages Report] The overall rat model market is expected to grow from USD 387.7 million in 2016 to USD 588.9 million by 2021, at a CAGR of 8.7% from 2016 to 2021. Continuous support in the form of investments and grants, and personalized medicine fueling the demand for personalized humanized rat models are some of the factors driving the growth of the rat model market. The rat model market is expanding with the increase in R&D activities in pharmaceutical industries. These rat model are being used in many applications such as toxicology, oncology, diabetes, neurology, immunology and infectious diseases, and others (rare disease, cardiovascular, metabolic disease, hematopoiesis, and regenerative medicines). The base year considered for rat model industry study is 2015, and the forecast has been provided for the period between 2016 and 2021.

Market Dynamics

Drivers

Advancements in gene editing tools set to augment the demand for rat models

Advantages offered by rats over mice

Continuous support in the form of investments and grants

Increased demand for personalized humanized rat models due to growing consumption of personalized medicines

Restraints

Regulations & laws formulated for ethical use of animals The Animal Welfare Act (AWA) Public health service policy (PHS) on humane care and use of laboratory animals

Increased benefits offered by cryopreservation

Opportunities

Increased production of monoclonal antibodies

Rising demand of humanized rat models

Challenges

Advancements in zebrafish model development

Development of methods alternative to animal testing

The development of advanced rat genome manipulation techniques (such as creation of transgenic rats and knockout rats), drives the global rat model market.

Preclinical animal models, such as mice and rats that are used to predict drug efficacy and toxicity in humans, are needed. Rats are commonly used due to their genetic similarity to humans as well as their unlimited supply and ease of manipulation. Knockout rats are produced by inactivating/silencing or "knocking out" an existing gene and replacing it with an artificial piece of DNA, thereby resulting in the loss of gene activity. This leads to changes in the rat�s phenotypic characteristics, such as appearance, behavior, and other observable biochemical characteristicsc. Knockout/genetically engineered rats segment is expected to grow at the highest CAGR during the forecast period. The high growth rate of knockout/genetically engineered rats segment can be attributed to the use of this type of rat model to carry out researches on disease such as oncology, obesity, heart disease, diabetes, arthritis, drug abuse, anxiety, aging, and Parkinson�s.

To get more details on this report,

The following are the major objectives of the study.

To describe and forecast the rat model market, in terms of value, by model type, technology, therapeutic area, end user, service, and care product.

To describe and forecast the rat model market, in terms of value, by region�Asia Pacific (APAC), Europe, North America, and Rest of the World (RoW) along with their respective countries

To provide detailed information regarding major factors influencing market growth (drivers, restraints, opportunities, and challenges)

To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market

To analyze opportunities in the market for stakeholders by identifying the high-growth segments of the rat model ecosystem

To strategically profile key players and comprehensively analyze their market position in terms of ranking and core competencies, along with detailing competitive landscape for market leaders

To analyze strategic approaches such as product launches, approvals, acquisitions, contracts, agreements, collaborations, and partnerships in the rat model market

During this research study, major players operating in the rat model market in various regions have been identified, and their offerings, regional presence, and distribution channels have been analyzed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Factiva, along with primary respondents. The entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) pertaining to the market. The figure below shows the breakdown of the primaries on the basis of the company type, designation, and region considered during the research study.

To get more details on this report,

The rat model market comprises a network of players involved in the research and product development; component manufacturing; distribution and sale; and post-sales services. Key players considered in the analysis of the rat model market are Charles River Laboratories International (US), Envigo (UK), and Taconic Biosciences (US).

Major Market Developments

In August 2016, Charles River Laboratories, Inc. entered into a strategic partnership with The Milner Therapeutics Institute and Consortium (UK). This partnership with the Consortium allows the academic institutions access to Charles River�s early discovery and drug development and services for the early stage drug development processes.

In September, 2016, Charles River Laboratories International, Inc. acquired Agilux Laboratories (US), a provider of bioanalytical services, drug metabolism and pharmacokinetic services, and pharmacology services. This acquisition is expected to compliment Charles River�s non-clinical portfolio and improve the clients� early-stage research efforts by enabling them to seamlessly transition their drug candidates through the discovery and safety assessment process.

In October 2015, Horizon Discovery Group plc expanded its UK based headquarters. The new facility is likely to accommodate 200 employees across manufacturing, services, research, and general and administrative functions.

Target Audience

Rat Model and Service Companies

Government and Private Research Institutes

Manufacturers and Suppliers of Animal Care Products

Academic & Research Institutes

Venture Capitalists

Medical Research Centers

Animal Care Associations

Public and Private Animal Health Agencies

Report Scope:

This research report categorizes the global rat model market into the following segments:

By Model Type

Outbred Rats

Inbred Rats

Knockout/Genetically Modified Rats

Hybrid/Congenic Rats

Conditioned/Surgically Modified Rats

Immunodeficient Rats

By Service

Breeding

Cryopreservation

Quarantine

Rederivation

Model-in-licensing

Genetic Testing

Other Services

By Therapeutic Area

Toxicology

Oncology

Immunology and Inflammation

Neurology

Diabetes

Other Therapeutic Areas

By Technology

CRISPR

Microinjection

Embryonic Stem Cell Injection

Nuclear Transfer

Other Technologies

By Care Product

Cages

Feed

Bedding

Other Care Products

By End User

Pharmaceutical & Biotechnology Companies

Academic & Research Institutes

Contract Research Organizations (CROs)

By Geography

North America

Europe

Asia-Pacific

Rest of the World

Available Customizations

Based on the given market data, MarketsandMarkets offers customizations in the reports as per the client�s specific requirements. The available customization options are as follows:

Geographic Analysis

Further country-wise breakdown of the market in APAC based on application

Company Information

Detailed analysis and profiling of additional market players (Up to 5)

The rat model market is expected to reach USD 588.9 million by 2021 from USD 387.7 million in 2016, at a CAGR of 8.7% from 2016 to 2021. The market is mainly driven by factors such as advancements in gene editing tools set to augment the demand for rat models, advantages offered by rats over mice, Continuous support in the form of investments and grants, and Increase in R&D activities carried out by pharmaceutical and biotechnology companies.

The global rat model market involves use of different varieties of rats (inbred rats, outbred rats, and hybrid rats, among others) in the research studies across the globe. Rat models are widely used as research models to study human genes and human diseases. Researchers in academia and industry as well as clinicians use rats extensively in their research works.

On the basis of type, the rat model market is segmented into outbred rats, inbred rats, knockout/genetically engineered rats, hybrid/congenic rats, conditioned/surgically modified rats, and immunodeficient rats model. Knockout/genetically engineered rats segment is expected to grow at the highest CAGR during the forecast period. The high growth rate of knockout/genetically engineered rats segment can be attributed to the use of this type of rat model to carry out researches on disease such as oncology, obesity, heart disease, diabetes, arthritis, drug abuse, anxiety, aging, and Parkinson�s.

On the basis of services, the rat model market is segmented into breeding, cryopreservation, quarantine, rederivation, model in-licensing, genetic testing, and others such as surgical services, line rescue services, and in vivo pharmacology services. The cryopreservation segment is estimated grow at the highest CAGR during the forecast period, as this segment help in obtaining the genetic material of rats even after the reproductive lifespan of these rats is over. This cuts down time and cost needed for reproduction of rats.

On the basis of technology, the rat model market is segmented into CRISPR, microinjection, embryonic stem cell injection, nuclear transfer technology, and others (genetically modified sperm-mediated gene transfer, Virus/vector-mediated gene transfer, Liposome-Mediated DNA Transfers, Electroporation of DNA, Biolistics, and TALENs & ZFN). The CRISPR segment accounted for the largest share of the rat model market in 2016. The large share of this segment is mainly attributed to its ease of use and ability to multiply.

On the basis of therapeutic area, the rat model market is segmented into toxicology, oncology, diabetes, neurology, immunology and infectious diseases, and others (rare disease, cardiovascular, metabolic disease, hematopoiesis, and regenerative medicines). The toxicology settings segment commanded the largest share of the rat model market in 2016. The large share of this segment can primarily be attributed to its use for new drug testing in preclinical stages, and toxicity and safety assessment studies.

On the basis of end users, the rat model market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, and Contract Research Organizations (CROs). The pharmaceutical & biotechnology companies segment commanded the largest share of the rat model market in 2016. The large share of this segment can primarily be attributed to the increasing R&D expenditure by companies.

Rat model applications in various therapeutic indications such as toxicology, oncology, diabetes, neurology, immunology and infectious diseases, and others (rare disease, cardiovascular, metabolic disease, hematopoiesis, and regenerative medicines) coupled with the increase in R&D activities carried out by pharmaceutical and biotechnology companies drive the growth of rat model market

TOXICOLOGY

Toxicology is the study of adverse effects of chemical, physical, or biological agents on people, animals, and the environment. Rats are predominantly used in the toxicity and safety assessment studies of a drug substance. Other animals that are used in these studies include mice, rabbits, and guinea pigs. Toxicology testing in animals is required to prove that the new drugs are safe before their administration in humans. A high proportion of new drugs fail in preclinical stage is due to the unacceptable toxicity in animals.

ONCOLOGY

Rat models recapitulate various aspects of genesis, progression, and clinical course of human cancers. Hence, they act as ideal study models for cancer researchers engaged in a variety of basic, translational, clinical, and epidemiological investigations.

IMMUNOLOGY AND INFLAMMATION

Rat models are used in immunology and inflammation studies as they help to assess the physiological relevance of an experimental finding. They also assist in identifying the functions of newly identified surface receptors in host defense as well as the developmental consequences of a disturbed signaling pathway or removing a transcription factor.

NEUROLOGY

Rat models serve as suitable animal models for detailed and accurate analysis of the mechanism of human neurodegenerative diseases. They help in the development and evaluation of new therapeutic strategies. Transgenic rat models are available for several neurological human conditions such as prion diseases, human retroviral diseases, Alzheimer�s disease, Parkinson�s disease, motor neuron diseases, anxiety, and others. Rat models for anxiety disorder have been useful for providing information on brain and behavioral mechanisms involved in the etiology and physiopathology of anxiety disorder.

DIABETES

Rats are considered to be excellent experimental models for understanding the complex genetic basis of diseases such as diabetes. Due to the ever-increasing prevalence of diabetes globally; it has become important to study the mechanism of the disease. However, it is quite difficult to carry out research studies in human beings, owing to problems such as genetic heterogeneity and lack of controlled lifestyles. Rat models act as suitable models to study specific genetic mutations and to understand the function of genes on a homogeneous genetic background.

Critical questions the report answers:

Which of the therapeutic application market will dominate in future?

Which regions will provide the high growth opportunities?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Regulations & laws formulated for ethical use of animals and increased benefits offered by cryopreservation are the major factor restraining the growth of the market. Various regulations and laws have been laid down by governments for ensuring ethical use of animals in research activities. Research institutes and companies carrying out studies on animals have to comply with these standards and requirements formulated for animal testing.

The key players in the global rat model market include Charles River Laboratories International (US), Envigo (UK), and Taconic Biosciences (US). Other players include Horizon Discovery Group (UK), genOway (France), Laboratory Corporation of America Holdings (US), Transposagen Biopharmaceuticals (US), Transviragen (US), Janvier Labs (France), and Biomere (US).